References
- Vastesaeger M., Gillot P., Rasson G. Etude clinique ďune nouvelle médication antiangoreuse. Acta Cardiol.Brux. 1967; 22: 483–500
- Coumel P., Bouvrain Y. Etude clinique des effets pharmaco-dynamique et antiarythmique de ľamiodarone. J. Agrégés. 1973; 6: 69
- Rosenbaum M. B., Chiale P. A., Halpern M. S., Nau G. J., Przybylski J., Levi R. J., Lazzari J. O., Elizari M. V. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am. J. Cardiol. 1976; 38: 934–944
- Heger J. J., Prystowsky E. N., Jackman W. M., Naccarelli G. V., Warfel K. A., Rinkenberger R. L., Zipes D. P. Amiodarone. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N. Engl. J. Med. 1981; 305: 539–545
- McKenna W. J., Harris L., Perez G., Krikler D. M., Oakely C., Goodwin J. F. Arrhythmia in hypertrophic cardiomyopathy. II. Comparison of amiodarone and verapamil in treatment. Br. Heart. J. 1981; 46: 173–178
- Nademanee K., Hendrickson J. A., Cannom D. S., Singh B. N. Refractory life-threatening ventricular arrhythmias: Control by amiodarone prophylaxis. Circulation 1980; 62: 151, suppl.III
- Marcus F. I., Fontaine G. H., Frank R., Grosgogeat Y. Clinical pharmacology and therapeutic applications of the antiarrhythmic agent, amiodarone. Am. Heart J. 1981; 101: 480–493
- Harris L., McKenna W. J., Rowland E., Holt D. W., Storey G. C.A., Krikler D. M. Side effects of long-term amiodarone therapy. Circulation 1983; 67: 45–51
- Rotmensch H. H., Belhassen B., Ferguson R. K. Amiodarone-benefits and risks in perspective. Am. Heart J. 1982; 104: 1117–1119
- Beckers C., Cornette C., Thalasso M. Evaluation of serum thyroxine by radioimmunoassay. J. Nuclear Med. 1973; 14: 317
- Bonati M., Gaspari F., D'Aranno E., Benfenati E., Neyroz P., Galletti F., Tognoni G. Physicochemical and analytical characteristics of amiodarone. J. Pharm.Sci., in press
- Finerman W. B., Jr., Hamer A., Peter T., Weiss D., Mandel W. J. Electrophysiologic effects of chronic amiodarone therapy in patients with ventricular arrhythmias. Am. Heart J. 1982; 104: 987–996
- Andreasen F., Agerbaek H., Bjerregaard P., Gøtzsche H. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur. J. Clin. Pharmacol. 1981; 19: 293–299
- Kannan R., Nademanee K., Hendrickson J. A., Rostami H. J., Singh B. N. Amiodarone kinetics after oral doses. Clin. Pharmacol. Ther. 1982; 31: 438–444
- Riva E., Gerna M., Latini R., Giani P., Volpi A., Maggioni A. Pharmacokinetics of amiodarone in man. J. Cardiovasc. Pharmacol. 1982; 4: 264–269
- Oreto G., Lapresa V., Melluso C., Manganaro A., Arrigo F. Intoxication aigue par 1′amiodarone. Arch.Mal. Coeur 1980; 73: 857–860
- Storey G. C.A., Adams P. C., Nicholson M. R., Campbell R. W.F., Holt D. W. Tissue concentrations of amiodarone and desethylamiodarone: Methodology and preliminary observations. Br. J. Clin. Pharmacol. 1983; 15: 148P–149P
- Maggioni A. P., Maggi A., Volpi A., D'Aranno V., Tognoni G., Giani P. Amiodarone distribution in human tissues after sudden death during holter recording. Am. J. Cardiol., in press